Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

8.7%

4 terminated/withdrawn out of 46 trials

Success Rate

88.2%

+1.7% vs industry average

Late-Stage Pipeline

57%

26 trials in Phase 3/4

Results Transparency

37%

11 of 30 completed trials have results

Key Signals

3 recruiting11 with results

Enrollment Performance

Analytics

Phase 4
14(37.8%)
Phase 3
12(32.4%)
Phase 1
6(16.2%)
Phase 2
5(13.5%)
37Total
Phase 4(14)
Phase 3(12)
Phase 1(6)
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (46)

Showing 20 of 46 trials
NCT07528040Not Yet Recruiting

An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

Role: collaborator

NCT07302360Recruiting

A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis

Role: lead

NCT07310095Phase 4Recruiting

A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)

Role: lead

NCT05387031Recruiting

Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease

Role: collaborator

NCT06082986Completed

A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China

Role: lead

NCT03617016Phase 4Completed

Preliminarily Evaluate the Efficacy of Domperidone in Adult Chinese Participants With Functional Dyspepsia

Role: lead

NCT05778097Phase 2Not Yet Recruiting

Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)

Role: collaborator

NCT04474938Phase 2Unknown

Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

Role: collaborator

NCT04514393Phase 2Unknown

Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

Role: collaborator

NCT04992377Phase 2Unknown

R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL

Role: collaborator

NCT03053024Completed

Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants

Role: lead

NCT03196531Phase 1Completed

A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets

Role: lead

NCT04094051Unknown

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Role: collaborator

NCT02895529Phase 4Terminated

A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy

Role: lead

NCT01692678Phase 3Completed

A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma

Role: lead

NCT03220867Phase 1Withdrawn

Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants

Role: lead

NCT01814098Phase 4Completed

An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms

Role: lead

NCT02228616Phase 4Completed

Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation

Role: lead

NCT03151720Phase 1Completed

A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets

Role: lead

NCT01870843Phase 4Completed

A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom

Role: lead